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Abstract
Objective: The effects of a promising pharmacological treatment for attention-deficit=hyperactivity disorder (ADHD),
atomoxetine, were studied on executive functions in both ADHD and reading disorder (RD) because earlier research
demonstrated an overlap in executive functioning deficits in both disorders. In addition, the effects of atomoxetine were
explored on lexical decision.
Methods: Sixteen children with ADHD, 20 children with ADHDþRD, 21 children with RD, and 26 normal controls were
enrolled in a randomized placebo-controlled crossover study. Children were measured on visuospatial working memory,
inhibition, and lexical decision on the day of randomization and following two 28-day medication periods.
Results: Children with ADHDþRD showed improved visuospatial working memory performance and, to a lesser extent,
improved inhibition following atomoxetine treatment compared to placebo.No differential effects of atomoxetinewere found
for lexical decision in comparison to placebo. In addition, no effects of atomoxetine were demonstrated in the ADHD and RD
groups.
Conclusion: Atomoxetine improved visuospatial working memory and to a lesser degree inhibition in children with
ADHDþRD, which suggests differential developmental pathways for co-morbid ADHDþRD as compared to ADHD and
RD alone.
Clinical Trial Registry: B4Z-MC-LYCK, NCT00191906; http:==clinicaltrials.gov=ct2=show=NCT00191906
Introduction
Deficits in executive functioning, especially inhibition andvisuospatial working memory, are hypothesized to be at the
heart of attention-deficit=hyperactivity disorder (ADHD) (Willcutt
et al. 2005). However, deficits in inhibitory control and in visuos-
patial working memory have been demonstrated in children with
reading disorder (RD) (Na¨rhi and Ahonen 1995; Purvis and Tan-
nock 2000; Martinussen and Tannock 2006). The common exec-
utive functioning deficits in ADHD and RD suggest that an
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effective treatment in ADHDmay also be effective in children with
both ADHD and RD and children with RD.
Stimulants are widely used in the pharmacological treatment of
ADHD. Because stimulants affect the striatum, they show abuse
and addictive potential (Volkow 2006). An effective alternative
pharmacological treatment to methylphenidate (MPH) is the nor-
adrenaline reuptake inhibitor atomoxetine, which shows no risk of
abuse because its site of action is presumed to be in the prefrontal
cortex and it does not increase dopamine in the nucleus accumbens
(Bymaster et al. 2002). Although the effects of atomoxetine on
ADHD symptoms have been promising and tested extensively, the
effects of atomoxetine on executive functioning are less studied
than those for MPH (Aron et al. 2003; Bedard et al. 2004; Kra-
tochvil et al 2006).
As far as we know, no studies have been reported that have
investigated the effects of atomoxetine on executive functioning in
children with ADHD. Only in adults with ADHD does there exist
some evidence for beneficial effects of atomoxetine on inhibition
(Spencer et al 1998; Faraone et al. 2005; Chamberlain et al. 2006;
Chamberlain et al. 2007). One aspect of inhibition, interference
control, as assessed by the Stroop Color and Word task, has been
shown to improve after 10 weeks of atomoxetine treatment in
comparison to placebo (Spencer et al. 1998). Faraone et al. (2005)
found weak evidence for an interference effect of atomoxetine in
comparison to placebo in subjects who scored relatively poorly at
baseline.
Improved inhibition in adults as assessed by Stop Signal Reac-
tion Time (SSRT) has been reported by Chamberlain et al. (2006,
2007). In both studies, SSRT improved (became faster) following a
single dose of atomoxetine (60mg) in healthy male volunteers as
well as in adults with ADHD compared to placebo. Atomoxetine,
however, showed no beneficial effects on visuospatial working
memory (Chamberlain et al. 2007). This was surprising because a
substantial body of research suggests that noradrenaline manipu-
lations in both animals and humans may affect component pro-
cesses of workingmemory (Coull et al. 1995; Arnsten and Li 2005).
The hypothesized role of noradrenaline has emphasized the main-
tenance of information in visuospatial working memory as mea-
sured by a delayed response task (Arnsten and Li 2005).
Chamberlain et al. (2007) used the Cambridge Neuropsychological
Test Automated Battery (CANTAB) Spatial Working Memory
task, which requires manipulation of information in working
memory and strategy implementation, possibly explaining the ab-
sence of effects of atomoxetine on visuospatial working memory.
In the present study, we focused on the beneficial effects of
atomoxetine on the maintenance function of visuospatial working
memory and inhibition in children with ADHD. Visuospatial
working memory was measured by the Corsi Block Tapping test, a
measure that taps on maintenance of information (Schellig 1997).
Inhibition was assessed by SSRT (Oosterlaan et al. 1998). To es-
tablish whether atomoxetine has effects on ADHD symptomatol-
ogy, a 28-day treatment period of atomoxetine was chosen.
No other study has yet tested the effects of medication in a co-
morbid ADHDþRD or RD only groups. We tested the effects of
atomoxetine in children with co-morbid ADHDþRD and children
with RD only. In addition, improvements in visuospatial working
memory and inhibition possibly lead to improvements in reading,
as assessed by a lexical decision task, because workingmemory and
inhibition are related to reading (Gijsel et al. 2004; Savage et al.
2007). Thus, the present study assessed the effects of atomoxetine
on lexical decision. The outcome of the effects of atomoxetine in
ADHD and RD may give indications of the validity of the hy-
pothesized common etiology of ADHD and RD. For example, if
atomoxetine is equally effective in children with ADHD and RD,
this may suggest a common etiology (Willcutt et al. 2005). How-
ever, when atomoxetine treatment is differentially effective in
children with ADHD only or RD only or ADHD and co-morbid
RD, this indicates that co-morbid ADHDþRD is a different dis-
order than ADHD or RD alone (Purvis and Tannock 2000).
The first goal of the current double-blind, placebo-controlled,
crossover study was to investigate the effects of atomoxetine in
children with ADHD, ADHDþRD, or RD on visuospatial working
memory and inhibition. A second goal was to study the effects of
atomoxetine on reading in children with ADHD, ADHDþRD, or
RD. To obtain more homogeneous groups, only children with the
combined subtype of ADHD were enrolled. Participants with other
co-morbid disorders other than RD and oppositional defiant dis-
order (ODD) were excluded.
Method
Participants
Children in the ADHD and ADHDþRD groups were recruited
via six pediatric outpatient clinics in The Netherlands and one
pediatric outpatient clinic in Belgium. Children in the RD group
were recruited via advertisements, because these children were not
regularly seen by pediatricians. A total of 16 children with ADHD,
21 children with RD, and 20 children with ADHDþRD completed
the study. Figure 1 displays eligible patients and reasons for
dropout. In addition, 26 normal controls, who were recruited in
regular primary schools, participated. The sample consisted of 102
children aged 8–12 years. Any child who dropped out during the
study was not entered in the analyses. Written informed consent
was obtained from the parents and from the child if aged 12 years.
The study was approved by the national research ethics committee
in The Netherlands and the local research ethics committee of the
participating sites.
Study procedure
The study consisted of two periods: Period I was the washout
period, if children were already on medication, and the screening
phase, in which informed consent was obtained and potential eli-
gibility determined. Eleven children in the ADHD group and 4
children in the ADHDþRD group received MPH prior to this
study. Period 1 had a duration of 1–62 days. In Period II, the
children with ADHD, ADHDþRD, and RD were randomly
assigned to the two treatment orders: Placebo–atomoxetine or
atomoxetine–placebo. Each treatment (placebo or atomoxetine)
lasted 28 days and was interspersed by a washout period of 14 days.
The (neuro)psychological measures were administered on the day
of randomization and immediately after the 28-day periods. Normal
controls performed the neuropsychological tests twice with an in-
terval of 28 days.
Medication
Placebo and atomoxetine were dispensed in a double-blind
fashion in identically appearing tablets, which contained 15, 25, 40,
50, 60, or 80mg of atomoxetine or lactose for the placebo pills.
Dose was based on the child’s weight and was initiated at ap-
proximately 0.6mg=kg per day for the first 7 days. The dose for the
next 21 days was 1.2mg=kg per day (mean dose¼ 1.11mg=kg per
day (standard deviation [SD]¼ 0.12mg=kg per day); range¼ 0.85–
1.33mg=kg per day). Atomoxetine and placebo were administered
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once daily in the morning or twice daily when children were unable
to tolerate a single dose. At each 28-day period, children returned
their unused pills to assess compliance, which was determined as
missing more than 2 consecutive days of full doses of medication or
failing to take at least 80% of prescribed medication. One patient
with ADHDþRD in the placebo period and 1 patient with RD in
the atomoxetine period were noncompliant. One patient in the
ADHD only group was noncompliant in both 28-day periods.
Normal controls did not receive medication.
Screening measures
All participants were screened for the presence of ADHD
combined subtype (ADHD-C) with the Disruptive Behavior Dis-
order Rating Scale (DBD) (Pelham et al. 1992; Oosterlaan et al.
2000). The parent version of the Diagnostic Interview Schedule for
Children (PDISC-IV) was administered (Ferdinand et al. 1998;
Shaffer et al. 2000). The PDISC-IV is based on the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
(American Psychiatric Association 1994) and the International
Classification of Diseases, 10th revision (ICD-10). A diagnosis of
ADHD-C was made if: (1) Parent and teacher scores on both the
Inattention and Hyperactivity=Impulsivity scales on the DBD fell
at least in the subclinical range (90th percentile) and (2) criteria
for ADHD-C on the PDISC-IV were met.
All children were thoroughly screened for the presence of RD
using two technical word reading tests, namely the One Minute
Test (OMT) (Brus and Voeten 1973) and the Pseudo-word Reading
Test (PRT) (Van den Bos et al. 1999), and one text reading test, the
Text Reading Test (TRT) (Visser et al. 1998). A diagnosis of RD
was made if children had at least 15 months delay on at least two of
the three reading tests. Normal controls, who met the criteria for
ADHD-C or any other subtype of ADHD or RD, were excluded.
Exclusion criteria for all groups
Children were excluded if they met criteria for obsessive com-
pulsive disorder (OCD), tic disorder (including Tourette’s disorder),
depression, or conduct disorder as assessed by the PDISC-IV. In
addition, children were excluded if they obtained a raw score of
40 or higher on the Children’s Depression Rating Scale (CDRS)
indicating major depression (Poznanski and Mokros 1996). Fur-
thermore, exclusion criteria were a prior or current diagnosis of
pervasive developmental disorder (PDD), anxiety disorder, post-
traumatic stress disorder (PTSD), and neurological disorders, such
as epilepsy as assessed by clinicians.
Children with severe arithmetic deficits were excluded as de-
fined by a delay greater than 20 school months on the Speeded
Arithmetic Test (SAT) (De Vos 1992), and a score below the 3rd
percentile on the Cognitive Subscales for Arithmetic (CSA) (De
Clerq et al. 2002).
Children were excluded if their estimated intelligence quotient
(IQ) was below 80, using four subtests of the Wechsler Intelligence
Scale for Children, 3rd edition (WISC-III): Picture Arrangement,
Arithmetic, Block Design, and Vocabulary (Sattler 1992).
Measures
ADHD symptomatology (ADHD-Rating Scale IV). The
ADHD Rating Scale-IV (ADHD-RS-IV) (DuPaul et al. 1998) was
used to measure change in ADHD symptoms in the ADHD and
ADHDþRD groups during the two 28-day treatment periods, as
rated by the investigator with the parent as rating source. The
ADHD-RS-IV consists of 18 items, with one item for each of the 18
symptoms of ADHD as listed in the DSM-IV. Each item is scored
on a 0–3 scale, which indicates the frequency of ADHD symptoms
in the child over the past week. Higher scores indicate more severe
symptoms.
Eligible Patients
(n=136)
Randomized
Patients
(n=76)
Screening Failures
(n=60)
Reasons:
n=54 Entry criteria not met
n= 4  Parent/caregiver decision
n=  1 Subject decision
n=  1 Other reason
Atomoxetine-Placebo
(n=39)
Placebo-Atomoxetine
(n=37)
Completed
(n=34)
Completed
(n=23)
Discontinued
(n=14)
Reasons:
n=9 Protocol violation
n=1  Adverse event
n=3  Subject decision
n=1  Parent/caregiver
decision
Discontinued
(n=5)
Reasons:
n=5 Protocol violation
FIG. 1. Patient flow diagram for the children that received treatment.
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Neuropsychological measures
Visuospatial Working Memory (Corsi Block Tapping
task). The Corsi Block Tapping task was administered to ex-
amine visuospatial working memory (Schellig 1997). Nine blocks
were displayed on a computer touch screen. A small cursor on the
screen tapped a sequence of blocks, starting with a two-block se-
quence that could be increased to nine blocks. After a tone, the child
had to retap the demonstrated sequence by touching the screen. The
test stopped when the child failed to complete two trials of a block
sequence. For each block sequence, there were two trials, which
could be extended with one trial when the first or second trial was
incorrect. The dependent variable was the total number of correct
trials, Number Correct Sequences.
Inhibition (Stop Signal Paradigm). The Stop Signal Para-
digm was administered to measure response inhibition (Oosterlaan
et al 1998; Lijffijt et al. 2005). In the first block of the task, children
had to indicate the position of a cartoon airplane on a computer
screen by pressing one of two spatially compatible response but-
tons. In the next five blocks, a cross was imposed on the cartoon
airplane in 25% of the trials, which indicated that the child had to
inhibit his response. Using a tracking mechanism, a 50% chance of
response inhibition was established by decreasing or increasing the
delay between the onset of the cartoon airplane and the cross, de-
pending on performance of the child (Logan and Cowan 1984).
SSRT can be determined by subtracting the mean delay time be-
tween the onset of the cartoon airplane and the cross from the mean
reaction time (MRT) on cartoon airplanes. Latency and accuracy of
the response execution process were also registered by MRT and
number of errors (omission and commission errors), respectively
(Band et al. 2003).
Lexical Decision making (Lexical Decision task). A lexical
decision task was administered to measure lexical decision skills
(Meyer and Schvaneveldt 1971). Participants had to discriminate
Valid Words from Pseudowords, which were presented individu-
ally on a computer screen. The practice block of 25 words was
followed by 5 blocks of each 25 Valid Words and 25 Pseudowords
presented in a pseudo-randomized manner.
The dependent variable was d0, which measured the accuracy
by which subjects correctly discriminated Valid Words from
Pseudowords, independent of response bias (Macmillan and
Creelman 1991). The hit rate and the false-positive rate of each
child were normalized by a probit function because responses were
binomial. In addition to d0, the MRT of correctly discriminated
Valid Words and Pseudowords was noted. The MRT for Valid
Words reflects the latency of lexical decision, because ValidWords
are hypothesized to be stored in the mental orthographical lexicon
(Manis et al. 1996). The MRT for Pseudowords indicates the la-
tency of the decoding process, because Pseudowords are not stored
in the mental lexicon. Pseudowords must be decoded, letter by
letter or by letter cluster, to determine what is written (Manis et al.
1996).
Data analysis
Seven data points for the visuospatial working memory task, the
Corsi Block Tapping task, were randomly missing due to technical
errors and were replaced by regression analysis (Tabachnick and
Fidell 2007). The lexical decision task was not administered to 1
child, because this child had not received sufficient reading in-
struction to complete this task. Results did not change after re-
moving noncompliant children; thus, these children were retained
in the analyses for power reasons. To reduce the influence of ex-
treme values, such values were replaced by the next most extreme
value in the distribution plus one unit (Tabachnick and Fidell
2007).
The data were analyzed by the groups who received treatment
(ADHD, ADHDþRD, and RD). To test for order effects of
treatment, the dependent measures were subjected to analyses of
variance (ANOVAs) with treatment as within-subject factor
(baseline, placebo, and atomoxetine) and as between-subject
factors, treatment order (placebo–atomoxetine or atomoxetine–
placebo), and group. When treatment order was not significant,
the dependent variables were subjected to an ANOVA with treat-
ment as a within-subject factor and group as a between-subject
factor. When an overall significant treatment effect and=or a
treatment by group interaction were found, repeated contrasts
were performed to compare placebo with atomoxetine. When the
placebo–atomoxetine repeated contrast led to a significant group by
treatment interaction, paired sample t-tests were performed per
group to study the origins of the interaction. For these paired
sample t-tests, the study-wide alpha level was adjusted for multiple
comparisons. Because the baseline-placebo comparison was not the
objective of this study, results of this comparison were left out of
the results text. The interested reader is referred to Table 1. Group
effects were tested with Tukey post hoc tests.
If a significant treatment order effect occurred (treatment by
treatment order interaction, or a treatment by treatment order by
group interaction), only data for the first 28-day medication period
were analyzed. An ANOVAwas conducted with visit (baseline and
visit after the first 28-day medication period) as within-subject
factor and treatment (placebo or atomoxetine) and group as
between-subject factors. Order effects were limited to MRT Valid
Words in the lexical decision task. The two orders (atomoxetine–
placebo or placebo–atomoxetine) did not lead to differences with
respect to baseline ADHD severity, reading, age, IQ, inhibition,
visuospatial working memory, and lexical decision.
When the placebo–atomoxetine comparison was significant, the
treatment groups were compared to normal controls to test whether
normalization occurred. Scores for the medication groups on pla-
cebo and atomoxetine were compared to the scores of the second
visit of normal controls to account for possible retest effects with
univariate ANOVAs. Tukey post hoc tests were used to test the
group differences further. Alpha was set at p< 0.05 for all com-
parisons except the paired sample t-tests.
Results
Group characteristics and results for the neuropsychological
measures are provided in Table 2.
ADHD symptomatology (ADHD-RS-IV)
A significant treatment effect was found on ADHD symptoms as
assessed by the ADHD-RS-IV (F[2,68]¼ 10.26, p< 0.001, Zp2¼
0.23). A repeated contrast revealed that ADHD symptoms dimin-
ished, after taking atomoxetine compared to placebo (F[1,34]¼
6.91, p< 0.013, Zp
2¼ 0.16). Treatment effects for atomoxetine
were comparable for children with ADHD and ADHDþRD, be-
cause no significant group by treatment interaction occurred in the
placebo–atomoxetine comparison. No significant effect of group
was found indicating that there was no significant difference in
ADHD symptoms between the ADHDþRD and ADHD-only
groups.
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Neuropsychological measures
Visuospatial Working Memory (Corsi Block Tapping
task). Treatment significantly improved visuospatial working
memory (F[2,108]¼ 20.52, p< 0.001, Zp2¼ 0.27). A repeated
contrast showed that a larger Number Correct Sequences was
completed with atomoxetine compared to placebo (F[1, 54]¼ 8.21,
p¼ 0.006, Zp2¼ 0.13). Groups differed in visuospatial working
memory (F[2,54]¼ 4.18, p¼ 0.02, Zp2¼ 0.13). Tukey post hoc
tests revealed that the ADHD group had a lower Number Correct
Sequences than either the RD or ADHDþRD groups ( p¼ 0.02
and p¼ 0.05, respectively). No significant differences occurred
between the ADHDþRD and RD groups ( p> 0.10).
A significant treatment by group interaction was observed for
visuospatial working memory (F(4,108)¼ 2.56, p¼ 0.042, Zp2¼
0.08). A repeated contrast indicated differential group effects after
taking atomoxetine compared to placebo (F[2,54]¼ 5.35, p¼
0.008, Zp
2¼ 0.16). Figure 2 shows that only children with
ADHDþRD had a larger Number Correct Sequences following
atomoxetine compared to placebo, which was confirmed by a sig-
nificant paired sample t-test ( p< 0.01). Paired sample t-tests for the
other two groups were not significant, all p values> 0.10.
Visuospatial working memory was poorer in children with
ADHD compared to both the ADHDþRD and RD groups. Ato-
moxetine improved visuospatial working memory only in the
ADHDþRD group.
Inhibition (Stop Signal Paradigm). Inhibitory control
(SSRT) was not affected by treatment nor were there significant
group differences in inhibitory control. A significant treatment by
group interaction was observed (F[4,108]¼ 2.48, p¼ 0.048,
Zp
2¼ 0.08). The contrast comparing atomoxetine to placebo mar-
ginally interacted with group (F[2,54]¼ 2.66, p¼ 0.07, Zp2¼
0.09). Figure 3 shows that only children with ADHDþRD had
faster SSRTs following atomoxetine compared to placebo, which
was supported by a nearly significant paired sample t-test, p¼ 0.07.
The paired sample t-test comparing SSRTs of the ADHDþRD and
RD groups on placebo and atomoxetine were not significant
( p> 0.10).
Speed of processing was significantly influenced by treatment
(F[2,108]¼ 16.74, p< 0.001, Zp2¼ 0.23). The effects of treatment
were due to a significant baseline-placebo comparison (see Table
1). Groups differed in MRT (F[2,54]¼ 3.93, p¼ 0.02, Zp2¼ 0.12).
Children with RD had slower MRTs than children with ADHD
( p¼ 0.02). MRTs of children with ADHDþRD fell between the
MRTs of the RD group and ADHD group, but did not significantly
differ from these two groups ( p> 0.10). No significant group-by-
treatment interaction was observed.
Accuracy was affected by treatment (F[2,108]¼ 6.39, p¼ 0.002,
Zp
2¼ 0.10), which was due to a significant baseline–placebo
comparison (see Table 1). The group effect escaped conventional
levels of significance (F[2, 54]¼ 3.05, p¼ 0.055, Zp2¼ 0.10). Tu-
key post hoc tests showed that children with RD made fewer errors
than children with ADHDþRD ( p¼ 0.006). The ADHD group did
not significantly differ from the RD and ADHDþRD groups (all p
values> 0.10). No significant group-by-treatment interaction was
observed.
Some evidence for beneficial effects of atomoxetine on inhibi-
tion as assessed by SSRT was found in the ADHDþRD group,
whereas atomoxetine did not impact the ADHD or RD groups in
this test.
Lexical Decision (Lexical Decision task). Lexical decision
accuracy, as assessed by d0, was not significantly influenced by
treatment. The group effect was marginally significant (F[2,53]¼
2.85, p¼ 0.066, Zp2¼ 0.09). Children with ADHDþRD had lower
d0 values than children with ADHD, although this group difference
fell shy of significance ( p¼ 0.057). No other significant group
differences or group-by-treatment interactions were found.
MRT Pseudowords showed a significant treatment effect
(F[2,106]¼ 3.14, p¼ 0.04, Zp2 0¼ 0.05). However, no significant
differences were found between either the baseline and placebo or
placebo and atomoxetine comparisons. No significant group dif-
ferences were observed for MRT Pseudowords nor a group-by-
treatment interaction occurred.
MRT Valid Words was affected by treatment order (F[2,49]¼
4.18, p¼ 0.02, Zp2¼ 0.14). Therefore, only data for the baseline
and the visit after the first 28-day medication period were analyzed.
No significant effects were observed for treatment or group.
To summarize, accuracy and speed of lexical decision and de-
coding were not influenced by atomoxetine.
Table 1. Results of the Baseline–Placebo Comparison
Treatment Treatment by group interaction
Measure F(1,54) Zp
2 F(2,54) Zp
2 Follow-up paired t-testa
Stop Signal Paradigm
SSRT 1.0 0.01 2.7 0.09 —
MRT 17.1b 0.2 0.2 0.008 —
Errors 9.5b 0.1 0.1 0.004 —
Corsi Block Tapping test
Number of Correct Sequences 13.6b 0.2 3.2c 0.1 ADHD, RD
Lexical decisiond
d0 2.8 0.04 1.0 0.04 —
MRT Pseudowords 1.8 0.03 0.7 0.02 —
aFollow-up paired t-tests tested for the effects of placebo as compared to baseline within each of the groups. Indicated groups showed significant effects
in the baseline-placebo comparison p< .05.
bSignificant at p< 0.01.
cSignificant at p< 0.05.
dOne child was missing.
Abbreviations: SSRT¼ stop signal reaction time; MRT¼mean reaction time; ADHD¼ attention-deficit=hyperactivity disorder; RD¼ reading
disorder.
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Normalization
To test whether performance normalized for variables that
showed an effect of atomoxetine, performance on placebo and
atomoxetine of the treatment groups was compared to the perfor-
mance of normal controls on their second visit. On placebo, groups
differed on visuospatial working memory (Number Correct Se-
quences) (F[3,79]¼ 3.15, p¼ 0.02, Zp2¼ 0.10). Tukey post hoc
tests showed that both the ADHD and the ADHDþRD groups had
poorer visuospatial working memory than normal controls
( p¼ 0.048 and p¼ 0.071, respectively). The RD group did not
differ from either group (all p values, p> 0.10). There was a group
effect following atomoxetine on visuospatial working memory
(F[3,79]¼ 4.51, p¼ 0.006, Zp2¼ 0.14). Only the ADHD group
remained different from normal controls ( p¼ 0.007) when treated
with atomoxetine ( p values for other groups, p> 0.10).
On placebo, groups marginally differed on SSRT (F[3,79]¼
2.36, p¼ 0.07, Zp2¼ 0.08). Tukey post hoc tests revealed that
SSRTs of the ADHDþRD group were marginally slower com-
pared to normal controls ( p¼ 0.08), all other group differences
Table 2. Group Characteristics and Neuropsychological Performance per Group and Condition
ADHD
n¼ 16
Males¼ 14
ADHDþRD
n¼ 20
Males¼ 15
RD
n¼ 21
Males¼ 8
NC
n¼ 26
Males¼ 16 Pairwise
comparisonsa
Variable M SD M SD M SD M SD (Tukey)
Age 8.8 1.3 9.8 1.2 9.9 1.0 9.3 0.9 ADHD<RD
IQ 99.3 14.0 94.5 8.2 100.0 7.2 107.3 9.4 ADHDþRD<NC
Mean dose=kg per day 1.11 0.12 1.14 0.11 1.06 0.13 — — N.S.
ADHD-RS-IV
Baseline 37.8 9.0 39.0 9.1 — — — — N.S.
Placebo 35.1 12.3 36.9 11.1 — — — —
Atomoxetine 32.2 13.4 26.4 13.7 — — — —
Stop Signal Task
SSRT
Baseline 285.3 67.2 284.1 72.2 284.9 64.1 245.7 56.2 N.S.
Placebo 279.4 52.1 296.5 85.2 254.2 66.0 249.2b 57.7b
Atomoxetine 294.2 83.1 263.0 43.8 261.8 77.8 — —
MRT
Baseline 549.6 64.8 564.3 81.1 613.1 117.2 501.3 63.0 RD<NC
Placebo 503.9 90.6 533.5 89.9 570.8 89.0 448.0b 72.1b
Atomoxetine 481.2 68.6 540.3 76.3 572.3 91.8
Errors
Baseline 9.7 8.5 13.0 11.5 8.0 7.3 4.2 4.0 ADHDþRD<NC
Placebo 7.3 5.7 9.8 7.8 4.4 3.6 6.0b 7.0b
Atomoxetine 7.5 5.0 9.8 7.5 5.6 6.6 — —
Corsi Block Tapping Test
Number correct sequences
Baseline 7.8 2.8 10.0 2.5 10.1 2.0 10.8 1.8 ADHD<ADHDþ
RD,RD, NC
Placebo 10.0 2.3 10.2 2.5 11.1 2.5 12.0b 2.2b
Atomoxetine 9.7 2.2 12.0 2.5 11.7 1.6 — —
Lexical decision task
d0
Baseline 2.5 0.5 1.9 0.7 2.2 1.0 3.0 0.6 ADHDþRD,RD<NC
Placebo 2.5 0.6 1.8 0.6 1.9 0.8 3.0b 0.7b
Atomoxetine 2.4 0.9 2.0 0.7 2.0 0.6 — —
MRT Valid Words
Baseline 1246.5 408.8 1251.8 415.9 1317.6 430.3 939.6 209.5 ADHDþRD, RD>NC
Placebo 1238.2 408.6 1298.0 407.9 1209.1 420.1 858.0b 211.4b
Atomoxetine 1096.9 281.5 1277.0 501.6 1180.0 401.6 —
MRT Pseudowords
Baseline 1410.0 437.8 1470.9 524.0 1572.0 467.6 1033.9 225.6 ADHD, ADHDþRD,
RD<NC
Placebo 1364.0 396.5 1469.0 495.6 1461.3 467.9 916.8b 237.5b
Atomoxetine 1247.7 371.4 1498.4 569.7 1415.4 537.3 — —
ap< 0.05.
bScores for the second visit of the normal control group.
Abbreviations: ADHD¼Attention-deficit=hyperactivity disorder; ADHD-RS-IV¼Attention-Deficit=Hyperactivity Disorder Rating Scale IV;
IQ¼ intelligence quotient; M¼mean; MRT¼mean reaction time; NC¼ normal controls; N.S.¼ not significant; RD¼ reading disorder; SD¼ standard
ndard deviation; SSRT¼ stop signal reaction time.
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were not significant ( p> 0.10). After taking atomoxetine, no sig-
nificant group differences were observed for SSRT (F[3,79]¼ 1.55,
p¼ 0.20, Zp2¼ 0.05).
Discussion
The first goal of this study was to examine the effects of ato-
moxetine on visuospatial working memory and inhibition in chil-
dren with ADHD, ADHDþRD, or RD. Visuospatial working
memory improved after taking atomoxetine in children with
ADHDþRD compared to placebo. Atomoxetine showed, com-
pared to placebo, a marginally significant positive effect on inhi-
bition in the ADHDþRD group. Both the ADHD and RD groups
showed no improved neuropsychological functioning following
atomoxetine. The second goal of this study was to determine pos-
sible effects of atomoxetine on lexical decision; no beneficial ef-
fects were found. Atomoxetine had the expected beneficial effects
on ADHD symptomatology compared to placebo.
Atomoxetine affected executive functioning only in children
with ADHDþRD, which suggests that ADHD and ADHDþRD
are not only different subtypes of ADHD at a neuropsychological
level (Purvis and Tannock 2000), but possibly also at the neuro-
chemical level (Halperin et al. 1997). Previous research suggests a
difference in noradrenaline levels between children with ADHD
and children with ADHDþRD. Children with ADHDþRD had
higher plasma levels of the noradrenaline metabolite 3-methoxy-4-
hydroxyphenylglycol (MHPG) than children with ADHD. MPHG
appeared to be inversely associated with academic achievement
and verbal processing, but was not related to behavior ratings or
measures of attention and impulsivity (Halperin et al. 1997).
As expected, atomoxetine improved the maintenance function
of visuospatial working memory. Although the exact mechanism
is unclear, working memory may be mediated by modulation of
the noradrenaline a2 receptor and the dopamine D1 receptor in
the prefrontal cortex (Arnsten and Li 2005). Atomoxetine in-
creases both noradrenaline and dopamine in the prefrontal cortex
(Bymaster et al. 2005), which may possibly be related to the
improved visuospatial working memory performance. It is unclear
whether verbal and visuospatial working memory tap the pre-
frontal cortex to the same extent, despite evidence that verbal
working memory is more left oriented and visuospatial working
memory is more right oriented in the brain (Smith and Jonides
1998). We did not include a measure of verbal working memory,
hence it was not possible to conclude whether atomoxetine im-
proves working memory in general or only visuospatial working
memory.
Lexical decision appeared insensitive to atomoxetine. Pre-
vious research indicated that visuospatial working memory was
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FIG. 2. Number Correct Sequences per group and treatment. Number Correct Sequences improved only in the ADHDþRD group
after taking atomoxetine in comparison to placebo. ADHD¼Attention-deficit=hyperactivity disorder; RD¼ reading disorder.
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FIG. 3. Mean SSRT per group and treatment. SSRT became faster only in children with ADHDþRD after taking atomoxetine in
comparison to placebo. SSRT¼ stop signal reaction time; ADHD¼ attention-deficit=hyperactivity disorder; RD¼ reading disorder.
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associated with reading ability (Savage et al. 2007). However, the
results of this study show no evidence of improvements in visuo-
spatial working memory leading to equivalent benefit in reading as
assessed by lexical decision.
The results should be interpreted in light of several limitations.
Mean dose (1.11 kg=day) was relatively low compared to other
studies with atomoxetine. Generally, other studies have used a
higher mean end dose because these studies were longer in duration
and titrated to 1.8mg=kg, when 1.2mg=kg was not effective after
4 weeks (Kratochvil et al. 2004; Crommen and Dankaerts 2005).
However, no relation was demonstrated between weight-adjusted
dose and our dependent variables. There was a relation between
absolute dose and score on ADHD-RS (r¼0.52, p¼ 0.001) and
the speed measures (MRT, r¼0.30, p¼ 0.01, MRT Valid
Words, r¼0.29, p¼ 0.02 and MRT Pseudowords, r¼0.27,
p¼ 0.041). Children with higher absolute doses were heavier and
thus generally older: However, a recent meta-analysis indicated no
relation between age and efficacy of atomoxetine (Cheng et al.
2007). Future research with higher absolute dose in larger groups
might reveal atomoxetine effects in children with ADHD and
children with RD in neuropsychological performance.
The results may be confounded by age and IQ, because the
groups differed in age and IQ.We have chosen not to covary for age
and IQ because age and IQ are related to the groups (Miller and
Chapman 2001). A lower IQ is consistently found in children with
ADHD (Frazier et al. 2004). Thus, covarying for IQ may remove
crucial variance. Differences in age are more or less inherent to the
disorders. To diagnose RD, a child must have followed 2–3 years of
reading education; in our sample, children with ADHDþRD and
RD were older than children with ADHD. Thus, age was related to
groups in a nonrandom fashion, which makes covarying for age
inappropriate.
Unfortunately, disproportionately more children had atomox-
etine than placebo in the first period (n¼ 34 and n¼ 23, respec-
tively). To test whether order influenced the results, we reran the
analyses with treatment order as covariate, which did not alter the
results. Thus, the findings on atomoxetine are not confounded by
placebo or learning effects in the first period.
In summary, this is the first study to demonstrate beneficial ef-
fects of atomoxetine on visuospatial working memory and to a
lesser extent inhibition in children with ADHDþRD. Atomoxetine
did not affect lexical decision and EF in children with ADHD and
children with RD. The present findings suggest there may be sep-
arate developmental pathways for co-morbid ADHDþRD and
ADHD or RD alone.
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